Chimezirim Ezeano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chimezirim Ezeano has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas Aderinto
Ladoke Akintola University of Technology, Ogbomosho, Nigeria
5 shared publications - Emmanuel Kokori
University of Ilorin, Ilorin, Nigeria
4 shared publications - Awoyinfa Michael Mbbs Oluwatobiloba
College of Medicine, University of Lagos, Lagos, Nigeria
2 shared publications Chike Onyali
Department of Internal Medicine, Jersey City Medical Center, Jersey City, USA
2 shared publications- Doyin Olatunji
Department of Health Sciences, Western Illinois University, Macomb, IL
2 shared publications - Israel Charles Abraham
University of Ilorin, Ilorin, Nigeria
2 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 548-553
Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence
Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 548-553
Open AccessIs there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence
Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.
- Open Access
- 26 September 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-10
The impact of fecal microbiota transplantation on refractory ulcerative colitis: A systematic review and Meta-Analysis of randomised controlled trials
Refractory ulcerative colitis (UC), characterized by persistent disease activity despite optimized medical therapy, poses a significant therapeutic challenge. Fecal microbiota transplantation (FMT) has shown promise in inducing remission in active ulcerative colitis (UC) by restoring gut microbial balance; however, its efficacy in refractory cases remains unclear. This systematic review and meta-analysis aimed to evaluate the effectiveness and safety of FMT in achieving clinical and endoscopic remission in patients with refractory UC, based on evidence from randomized controlled trials (RCTs). We searched PubMed, Scopus, Google Scholar Cochrane CENTRAL, and Web of Science up to February 2025 for RCTs comparing FMT to placebo or standard care in adults with refractory UC (Mayo Score ≥ 3 despite treatment). Primary outcomes were clinical remission (Mayo Score ≤ 2, no subscore > 1) and endoscopic remission (Mayo endoscopic subscore ≤ 1). Data were pooled using a random-effects model, with heterogeneity assessed via I² and Q-tests. Subgroup analyses explored age at diagnosis and disease duration as moderators. The review followed PRISMA guidelines and was registered with PROSPERO (CRD420250651790). Six RCTs were included. FMT showed no significant effect on clinical remission (pooled estimate − 0.2584; 95% CI − 0.9031 to 0.3863; p = 0.4321) or endoscopic remission (pooled estimate − 0.2229; 95% CI − 0.8811 to 0.4353; p = 0.5069), with no heterogeneity (I² = 0.00%). Subgroup analyses revealed no moderation by age or disease duration (p > 0.27). Adverse events were mild and transient. FMT does not significantly improve clinical or endoscopic remission in refractory UC, suggesting limited efficacy in this population despite a favorable safety profile. Larger, standardized trials are warranted.
- 26 September 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-10
Open AccessThe impact of fecal microbiota transplantation on refractory ulcerative colitis: A systematic review and Meta-Analysis of randomised controlled trials
Refractory ulcerative colitis (UC), characterized by persistent disease activity despite optimized medical therapy, poses a significant therapeutic challenge. Fecal microbiota transplantation (FMT) has shown promise in inducing remission in active ulcerative colitis (UC) by restoring gut microbial balance; however, its efficacy in refractory cases remains unclear. This systematic review and meta-analysis aimed to evaluate the effectiveness and safety of FMT in achieving clinical and endoscopic remission in patients with refractory UC, based on evidence from randomized controlled trials (RCTs). We searched PubMed, Scopus, Google Scholar Cochrane CENTRAL, and Web of Science up to February 2025 for RCTs comparing FMT to placebo or standard care in adults with refractory UC (Mayo Score ≥ 3 despite treatment). Primary outcomes were clinical remission (Mayo Score ≤ 2, no subscore > 1) and endoscopic remission (Mayo endoscopic subscore ≤ 1). Data were pooled using a random-effects model, with heterogeneity assessed via I² and Q-tests. Subgroup analyses explored age at diagnosis and disease duration as moderators. The review followed PRISMA guidelines and was registered with PROSPERO (CRD420250651790). Six RCTs were included. FMT showed no significant effect on clinical remission (pooled estimate − 0.2584; 95% CI − 0.9031 to 0.3863; p = 0.4321) or endoscopic remission (pooled estimate − 0.2229; 95% CI − 0.8811 to 0.4353; p = 0.5069), with no heterogeneity (I² = 0.00%). Subgroup analyses revealed no moderation by age or disease duration (p > 0.27). Adverse events were mild and transient. FMT does not significantly improve clinical or endoscopic remission in refractory UC, suggesting limited efficacy in this population despite a favorable safety profile. Larger, standardized trials are warranted.
- Open Access
- 4 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (27) , e43071
A review of proton beam therapy’s role in glioma management
Gliomas pose significant therapeutic challenges due to limited survival and risks of treatment-related toxicity. Proton beam therapy (PBT) offers a precise radiation delivery method, minimizing damage to healthy brain tissue compared to conventional radiotherapy. This review synthesizes findings from 15 studies (2000–January 2024) from PubMed, Google Scholar, Science Direct, Cochrane Library, and Directory of Open Access Journals. PBT significantly reduces neurocognitive decline and enhances quality of life while achieving comparable or superior survival outcomes across various glioma types, including low-grade gliomas and glioblastomas. Notable benefits include improved verbal memory, stable intellectual functioning, and reduced high-grade toxicity. However, challenges such as neuroendocrine deficiencies and increased radiation necrosis highlight the need for optimized protocols. Future research should focus on comprehensive outcome assessments, proactive management of adverse effects, and improving PBT accessibility through cost reduction and technological advancements. PBT holds transformative potential in glioma management, balancing effective tumor control with preservation of neurological function, positioning it as a valuable neuro-oncology treatment option.
- 4 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (27) , e43071
Open AccessA review of proton beam therapy’s role in glioma management
Gliomas pose significant therapeutic challenges due to limited survival and risks of treatment-related toxicity. Proton beam therapy (PBT) offers a precise radiation delivery method, minimizing damage to healthy brain tissue compared to conventional radiotherapy. This review synthesizes findings from 15 studies (2000–January 2024) from PubMed, Google Scholar, Science Direct, Cochrane Library, and Directory of Open Access Journals. PBT significantly reduces neurocognitive decline and enhances quality of life while achieving comparable or superior survival outcomes across various glioma types, including low-grade gliomas and glioblastomas. Notable benefits include improved verbal memory, stable intellectual functioning, and reduced high-grade toxicity. However, challenges such as neuroendocrine deficiencies and increased radiation necrosis highlight the need for optimized protocols. Future research should focus on comprehensive outcome assessments, proactive management of adverse effects, and improving PBT accessibility through cost reduction and technological advancements. PBT holds transformative potential in glioma management, balancing effective tumor control with preservation of neurological function, positioning it as a valuable neuro-oncology treatment option.
- Open Access
- 20 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery: Global Health
- Vol. 8 (4)
Efficacy and safety of Seladelpar in the treatment of primary biliary cholangitis: a systematic review and meta-analysis
Background: Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease marked by destruction of intrahepatic bile ducts, leading to fibrosis, cirrhosis, and liver failure. Current treatments, including ursodeoxycholic acid and obeticholic acid, are often inadequate or associated with adverse effects, highlighting the unmet need for effective, well-tolerated therapies. Seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, has shown promise in improving biochemical markers and clinical outcomes in PBC. This systematic review and meta-analysis evaluates the efficacy and safety of Seladelpar in PBC management. Methods: This review adhered to PRISMA guidelines and was registered with PROSPERO. A systematic search of PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov was conducted up to October 2024, focusing on studies evaluating Seladelpar in adult PBC patients. Randomized controlled trials, observational studies, and open-label extensions reporting efficacy (e.g., alkaline phosphatase [ALP] reduction) or safety outcomes were included. Meta-analysis was performed using RevMan, with pooled estimates presented as weighted mean differences or risk ratios. Results: From 611 studies, seven met inclusion criteria, comprising 1019 participants across Phase 2 and Phase 3 trials and open-label extensions. Seladelpar significantly reduced ALP levels, with a dose-response relationship observed. The 10 mg dose showed the most pronounced efficacy, with a 53–63% ALP reduction compared to placebo. Clinical improvements, including reduced pruritus and enhanced quality of life, were consistent across studies. Long-term follow-up demonstrated sustained biochemical and clinical benefits. Adverse effects were dose-dependent, with pruritus, nausea, and dyspepsia most common. The 5 mg dose had the lowest incidence of adverse events. Conclusions: Seladelpar demonstrates robust efficacy in improving biochemical markers and alleviating symptoms in PBC, with a favorable safety profile. Its potential for long-term clinical benefit underscores its role as a promising therapeutic option for patients with PBC. Further studies are warranted to confirm its long-term safety and efficacy in diverse patient populations.
- 20 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery: Global Health
- Vol. 8 (4)
Open AccessEfficacy and safety of Seladelpar in the treatment of primary biliary cholangitis: a systematic review and meta-analysis
Background: Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease marked by destruction of intrahepatic bile ducts, leading to fibrosis, cirrhosis, and liver failure. Current treatments, including ursodeoxycholic acid and obeticholic acid, are often inadequate or associated with adverse effects, highlighting the unmet need for effective, well-tolerated therapies. Seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, has shown promise in improving biochemical markers and clinical outcomes in PBC. This systematic review and meta-analysis evaluates the efficacy and safety of Seladelpar in PBC management. Methods: This review adhered to PRISMA guidelines and was registered with PROSPERO. A systematic search of PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov was conducted up to October 2024, focusing on studies evaluating Seladelpar in adult PBC patients. Randomized controlled trials, observational studies, and open-label extensions reporting efficacy (e.g., alkaline phosphatase [ALP] reduction) or safety outcomes were included. Meta-analysis was performed using RevMan, with pooled estimates presented as weighted mean differences or risk ratios. Results: From 611 studies, seven met inclusion criteria, comprising 1019 participants across Phase 2 and Phase 3 trials and open-label extensions. Seladelpar significantly reduced ALP levels, with a dose-response relationship observed. The 10 mg dose showed the most pronounced efficacy, with a 53–63% ALP reduction compared to placebo. Clinical improvements, including reduced pruritus and enhanced quality of life, were consistent across studies. Long-term follow-up demonstrated sustained biochemical and clinical benefits. Adverse effects were dose-dependent, with pruritus, nausea, and dyspepsia most common. The 5 mg dose had the lowest incidence of adverse events. Conclusions: Seladelpar demonstrates robust efficacy in improving biochemical markers and alleviating symptoms in PBC, with a favorable safety profile. Its potential for long-term clinical benefit underscores its role as a promising therapeutic option for patients with PBC. Further studies are warranted to confirm its long-term safety and efficacy in diverse patient populations.
- Open Access
- 11 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (41) , e40084
A review of exercise interventions for reducing anxiety symptoms: Insights and implications
Generalized anxiety disorder (GAD) is a prevalent mental health condition affecting a significant proportion of the adult population. Despite the availability of pharmacological treatments, their long-term efficacy and potential side effects necessitate exploring alternative interventions. Aerobic exercise has emerged as a promising non-pharmacological approach for managing anxiety symptoms in individuals with GAD. This narrative review examines the efficacy of aerobic exercise interventions in alleviating symptoms of anxiety disorders, drawing on a comprehensive analysis of relevant literature. The review synthesizes findings from studies investigating various forms of aerobic exercise, including high-intensity interval training, resistance training, Pilates, and walking. The results indicate that aerobic exercise interventions demonstrate efficacy in reducing anxiety symptoms and improving overall well-being across diverse populations, including primary care patients, individuals with coronary heart disease, and older adults with cancer undergoing chemotherapy. The review discusses the neurobiological and psychological mechanisms underlying the anxiolytic effects of aerobic exercise. It highlights the implications of these findings for clinical practice, public health initiatives, and future research directions. Despite the promising evidence, limitations in study methodologies and heterogeneity across interventions warrant a cautious interpretation of the results. Further research is needed to elucidate optimal exercise modalities, dosages, and long-term effects on anxiety outcomes.
- 11 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (41) , e40084
Open AccessA review of exercise interventions for reducing anxiety symptoms: Insights and implications
Generalized anxiety disorder (GAD) is a prevalent mental health condition affecting a significant proportion of the adult population. Despite the availability of pharmacological treatments, their long-term efficacy and potential side effects necessitate exploring alternative interventions. Aerobic exercise has emerged as a promising non-pharmacological approach for managing anxiety symptoms in individuals with GAD. This narrative review examines the efficacy of aerobic exercise interventions in alleviating symptoms of anxiety disorders, drawing on a comprehensive analysis of relevant literature. The review synthesizes findings from studies investigating various forms of aerobic exercise, including high-intensity interval training, resistance training, Pilates, and walking. The results indicate that aerobic exercise interventions demonstrate efficacy in reducing anxiety symptoms and improving overall well-being across diverse populations, including primary care patients, individuals with coronary heart disease, and older adults with cancer undergoing chemotherapy. The review discusses the neurobiological and psychological mechanisms underlying the anxiolytic effects of aerobic exercise. It highlights the implications of these findings for clinical practice, public health initiatives, and future research directions. Despite the promising evidence, limitations in study methodologies and heterogeneity across interventions warrant a cautious interpretation of the results. Further research is needed to elucidate optimal exercise modalities, dosages, and long-term effects on anxiety outcomes.
- Open Access
- 28 June 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (26) , e38767
A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy
Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis), known as Corino de Andrade disease, is a rare neurodegenerative disorder with a significant global impact characterized by the misfolding of transthyretin (TTR) protein leading to amyloid aggregation, ATTRv amyloidosis, especially with polyneuropathy, poses a considerable challenge in managing its rapid progression and debilitating effects. This mini-review focuses on the recent advancements in the treatment landscape for ATTRv amyloidosis with polyneuropathy, specifically the RNA interference therapeutic Vutrisiran and the ligand-conjugated antisense oligonucleotide Eplontersen. We aim to provide a comprehensive overview of the mechanisms, current evidence from clinical trials, and future directions for these novel therapeutic agents. Vutrisiran and Eplontersen have demonstrated significant clinical efficacy in improving neuropathic impairment, quality of life, and serum TTR levels in various trials. The distinct mechanistic approaches of these therapies, coupled with their acceptable safety profiles, offer promising avenues for addressing the complexities of ATTRv amyloidosis with polyneuropathy. The introduction of Vutrisiran and Eplontersen marks a pivotal moment in the quest for effective therapies against ATTRv amyloidosis with polyneuropathy. While clinical evidence is promising, ongoing research is crucial to deepen mechanistic understanding and address research gaps. Future perspectives include the potential expansion of therapeutic options and a more inclusive approach to cater to the diverse needs of individuals globally. This mini-review provides valuable insights into the evolving landscape of ATTRv amyloidosis management and sets the stage for further exploration in this challenging domain.
- 28 June 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (26) , e38767
Open AccessA mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy
Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis), known as Corino de Andrade disease, is a rare neurodegenerative disorder with a significant global impact characterized by the misfolding of transthyretin (TTR) protein leading to amyloid aggregation, ATTRv amyloidosis, especially with polyneuropathy, poses a considerable challenge in managing its rapid progression and debilitating effects. This mini-review focuses on the recent advancements in the treatment landscape for ATTRv amyloidosis with polyneuropathy, specifically the RNA interference therapeutic Vutrisiran and the ligand-conjugated antisense oligonucleotide Eplontersen. We aim to provide a comprehensive overview of the mechanisms, current evidence from clinical trials, and future directions for these novel therapeutic agents. Vutrisiran and Eplontersen have demonstrated significant clinical efficacy in improving neuropathic impairment, quality of life, and serum TTR levels in various trials. The distinct mechanistic approaches of these therapies, coupled with their acceptable safety profiles, offer promising avenues for addressing the complexities of ATTRv amyloidosis with polyneuropathy. The introduction of Vutrisiran and Eplontersen marks a pivotal moment in the quest for effective therapies against ATTRv amyloidosis with polyneuropathy. While clinical evidence is promising, ongoing research is crucial to deepen mechanistic understanding and address research gaps. Future perspectives include the potential expansion of therapeutic options and a more inclusive approach to cater to the diverse needs of individuals globally. This mini-review provides valuable insights into the evolving landscape of ATTRv amyloidosis management and sets the stage for further exploration in this challenging domain.
- Open Access
- 10 June 2024
- Published by IntechOpen
Neurocysticercosis and the Central Nervous System: Advancements in Diagnosis, Treatment, and Future Prospects
Neurocysticercosis presents a formidable global health challenge. This parasitic infection induces cystic lesions, primarily in the brain and spinal cord, leading to neurological symptoms and complications. Global prevalence varies, driven by socioeconomic conditions, cultural practices, and dietary habits, particularly in low and middle-income countries. Diagnosis remains challenging, relying on clinical, serological, and neuroimaging findings, with advanced tools like CT and MRI scans enhancing accuracy. Treatment strategies involve antiparasitic medications, anti-inflammatory drugs, and surgical interventions. Ongoing research explores innovative diagnostics and treatments, emphasising a comprehensive, individualised approach. A One Health approach, integrating human, animal, and environmental health, is crucial for effective prevention. Exploring the socioeconomic impacts, ethical considerations, and technology integration, including telemedicine, is paramount. Understanding cultural factors influencing healthcare-seeking behaviour contributes to culturally sensitive interventions. Technology integration can improve diagnostic capabilities and healthcare access, especially in regions with limited resources.
- 10 June 2024
- Published by IntechOpen
Open AccessNeurocysticercosis and the Central Nervous System: Advancements in Diagnosis, Treatment, and Future Prospects
Neurocysticercosis presents a formidable global health challenge. This parasitic infection induces cystic lesions, primarily in the brain and spinal cord, leading to neurological symptoms and complications. Global prevalence varies, driven by socioeconomic conditions, cultural practices, and dietary habits, particularly in low and middle-income countries. Diagnosis remains challenging, relying on clinical, serological, and neuroimaging findings, with advanced tools like CT and MRI scans enhancing accuracy. Treatment strategies involve antiparasitic medications, anti-inflammatory drugs, and surgical interventions. Ongoing research explores innovative diagnostics and treatments, emphasising a comprehensive, individualised approach. A One Health approach, integrating human, animal, and environmental health, is crucial for effective prevention. Exploring the socioeconomic impacts, ethical considerations, and technology integration, including telemedicine, is paramount. Understanding cultural factors influencing healthcare-seeking behaviour contributes to culturally sensitive interventions. Technology integration can improve diagnostic capabilities and healthcare access, especially in regions with limited resources.